If you attended our recent webinar “Harnessing the Power of mHealth for New, Better Data and Improved Patient Engagement” you had the opportunity to submit a question to BBK President Matt Kibby or Roche Operational Intelligence Leader, Lewis Millen, during the webinar’s Q&A portion. We received so many great and thoughtful questions from our attendees, that we were, unfortunately, unable to address all of them. Today, we are happy to share Matt’s responses to many of those questions here, and we hope you find his answers useful.
During last week’s webinar with BBK President Matt Kibby and Roche’s Operational Intelligence Leader, Lewis Millen, on “Harnessing the Power of mHealth for New, Better Data and Improved Patient Engagement,” we had the opportunity to cover a variety of topics and challenges related to mHealth adoption and deployment. And we were pleased to have so many representatives from all areas of clinical R&D, including patients, join us. Lewis was able to provide such valuable insights and if you joined us, you know that first hand.
At BBK Worldwide, we are committed to improving patient engagement through patient-centric technologies and best-practices. Alongside our clinical research partners, we work to boost clinical trial awareness and simplify the clinical trial experience for patients and sites. As the healthcare industry reaffirms its commitment to improving the pathways to improved clinical research, BBK will host Harnessing the Power of mHealth for New, Better Data and Improved Patient Engagement, a webinar to discuss what's needed to leverage the power of mHealth and related technologies to the benefit of the study and the study patient on Friday, October 28, 2016 at 12:00 p.m. ET.
Late last month, BBK hosted the webinar Rare Disease 20/20: A Look at the Challenges and Opportunities in Rare Disease Clinical R&D giving our listeners the opportunity to gain insights from thought leaders in rare disease patient advocacy and orphan drug development.
To raise awareness with policy makers and the public of rare diseases and of their impact on the lives of patients and their loved ones, the National Organization for Rare Disorders (NORD) established Rare Disease Day® in the U.S. almost seven years ago. Since then, people all over the world have come together to inform the public and engage with policy makers, researchers, health professionals and more, affecting positive change for all those impacted by rare diseases.
Mobile devices and apps which monitor vital signs, analyze blood, and track medication adherence, among other things are quickly becoming the new norm in healthcare. But how is mHealth making its mark on clinical trials? A recent survey conducted by Applied Clinical Trials and SCORR Marketing confirms that mobile health technology is in fact poised to improve data collection and quality, and drive efficiencies across the clinical trial landscape.
During our recent webinar, "Patient-centric to the Core", attendees asked great, thought-provoking questions of our panelists, Christel Aprigliano (The Diabetes Collective), Claire Meunier (The Michael J. Fox Foundation), and Bonnie A. Brescia (BBK Worldwide). We answered some during the webinar, but ran out of time and couldn’t get to them all. A full summary of webinar Q&As follow; we hope it helps address some of your own questions, thoughts and concerns. If you have others, please join the conversation by posting a question in the comment section below. Also, stay tuned for an upcoming BBK eBook on this highly discussed topic.
If you're not putting your patients first, someone else will. Yesterday, BBK hosted a webinar on patient centricity in clinical research. The webinar, Patient-centric to the Core: Setting a New Standard for Engagement Strategies in Clinical Research, addresses the topic of how patient centricity is no longer a nice-to-have; it is a critical component of any study's success.
Founded in 1983 with a $30,000 loan and two military surplus desks, BBK Worldwide has become a global, multi-million dollar corporation that is changing the face of patient recruitment for clinical R&D in the pharma and biopharma industries. Today, our founding principals, Bonnie A. Brescia and Joan F. Bachenheimer have created a global enterprise – one that that is true to their philosophies of how a business, its products, services, and culture can create new opportunities for its staff, clients and benefit consumers.
If you’re not putting your patients first, someone else will. Patient-centricity is no longer a nice-to-have; it is a critical component of any study’s success. Thoughtful and effective patient engagement and retention strategies should be employed throughout the entire clinical trial process – and the patient’s contribution to clinical research and the advancement of treatment options cannot be underestimated. Regardless of the inherent complexities of study management, clinical trial sponsors have an obligation to ensure patients have the best clinical trial experience possible.